NIH opens Wb4B filariasis diagnostic invention to commercial licensing

The story

The U.S. National Institutes of Health has opened a government-owned lymphatic-filariasis diagnostic invention to commercial licensing and research collaboration. A Federal Register notice published October 27 offers the Wb4B antigen sequence, expression plasmids and related assay technology developed by National Institute of Allergy and Infectious Diseases researchers Thomas B. Nutman and Sasisekhar Bennuru. The goal is a more specific way to detect infection by Wuchereria bancrofti or Brugia malayi, two mosquito-borne parasites that cause the disabling disease also known as elephantiasis.

This is not a market-ready test. NIH describes the technology as preclinical and says only that preliminary work with sera from affected people indicates Wb4 can detect B. malayi. Wb4B is a modified recombinant version that removes the first 19 amino acids—the protein’s signal sequence. According to the notice and patent specification, that change appears to make the antigen easier to express and purify in a bacterial system while improving its immunoassay response. Those observations still require larger, independently reported clinical studies.

The intellectual-property package is broader than a single purified protein. PCT application WO2026019730A1 claims Wb4 proteins and antigenic fragments linked to reporters or tags, the nucleic acids and vectors used to produce them, host cells and methods for detecting antibodies in patient samples. The specification describes luciferase immunoprecipitation, ELISA and lateral-flow formats. It also sketches a multiplex strip combining Wb4 with the NIAID biomarkers Wb5 or Wb123 so one assay could cover different parasite species or improve detection across stages of infection.

That combination is the commercial hypothesis, not a demonstrated product claim. The patent reports testing on human and animal sera, including archived and pooled samples, and says Wb4B has been expressed and purified in E. coli. It does not establish that a manufactured strip will meet public-health performance requirements across diverse populations. The Federal Register notice explicitly invites companies or research partners to further develop, evaluate and commercialise the technology under HHS reference E-067-2024-0.

The diagnostic gap is consequential. WHO’s October progress report says 361 million people were estimated to require mass drug administration for lymphatic filariasis in 2025, while 244.2 million were treated. As countries suppress transmission and stop mass treatment, surveillance has to identify residual infection or a rebound before it spreads. WHO currently recommends blood-smear microscopy, a filariasis test strip for W. bancrofti antigen and a Brugia rapid antibody test in specified programme settings. It also says work continues to validate new antibody-based rapid tests for post-treatment surveillance.

Cross-reactivity makes that work difficult. Filarial infections can share geography, and antibodies raised against one parasite may respond to another antigen. A test that cannot distinguish lymphatic filariasis from Onchocerca volvulus or Loa loa can distort prevalence estimates and trigger the wrong programme decisions. NIH says Wb4 is aimed at that specificity problem, but the notice does not publish a complete sensitivity-and-specificity table for Wb4B.

Independent context comes from a peer-reviewed 2025 PLOS study of Wb5 by several of the same researchers and external collaborators. Wb5 showed minimal cross-reactivity with sera from other helminth infections, but on its own detected only 53.68 percent of positive cases at 100 percent specificity. Combining Wb5 with Wb123 raised sensitivity to 81 percent—still below WHO’s minimum target of more than 85 percent for a surveillance test. The result supports the logic of multiplexing while also showing why promising specificity does not complete the validation problem.

WHO’s target product profile sets a demanding bar: above 85 percent sensitivity and 98.8 percent specificity at minimum, with preferred performance above 99 and 99.8 percent respectively. The preferred test uses a finger-prick sample, works under zero-infrastructure conditions, returns a result within 30 minutes and remains stable without a cold chain. Wb4B’s manufacturability may help, but the public documents do not yet show those product characteristics.

INNOVOX analysis: this is a technology-transfer story more than a diagnostic breakthrough. NIH has moved a defined antigen, production materials and patent rights into a form that a company can license, manufacture and test. That can shorten the path from laboratory discovery to field evaluation, especially for neglected diseases with limited commercial incentives. Yet licensing is only the bridge. A developer still has to finance assay engineering, multi-country validation, quality-controlled production and regulatory review.

What to watch is whether a licensee publishes transparent performance data rather than relying on the patent’s examples. The most informative study would compare a Wb4-based multiplex assay with WHO-recommended tests in countries where W. bancrofti, Brugia and other filariae overlap, then follow treated communities to see whether antibody signals track active infection or linger after clearance. Until that evidence exists, Wb4B is a credible invention available for development—not proof that the surveillance gap has been solved.

INNOVOX analysis

The licensing notice matters because it packages a publicly funded biomarker with production plasmids and a broad assay patent into a commercialisation opportunity. The decisive value will not be the existence of another antigen, but whether a developer can turn Wb4B into an affordable multiplex test that clears demanding surveillance thresholds in places where several filarial parasites overlap.

What to watch

Watch for a named licensee, public clinical datasets for Wb4B, head-to-head testing against WHO-recommended tools, performance in Brugia- and Loa-endemic settings, and a field-ready format that meets WHO requirements for sensitivity, specificity, heat stability and minimal sample volume.